Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
Top

14-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article

Researcher comment: The ORAL Shift trial

print
PRINT
insite
SEARCH

​​​​​​Stanley Cohen discusses the latest findings from the trial looking at methotrexate withdrawal in patients with rheumatoid arthritis achieving low disease activity with tofacitinib (2:11).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.


print
PRINT

Related content

17-06-2019 | Rheumatoid arthritis | EULAR 2019 | News

Methotrexate withdrawal feasible with tofacitinib in patients with RA

04-08-2017 | Rheumatoid arthritis | Feature | Article

At a glance: The ORAL trials of tofacitinib for the treatment of RA

29-03-2019 | Rheumatoid arthritis | Feature | Article

JAK inhibitors in RA: A round-up of the phase 3 trials
Image Credits